Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 12/20 | 0.65 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.65 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | UBE2N | P61088 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7280328 | 0.99 | PDE5A (0.63) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL5595125 | 0.87 | PDE5A (0.69) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| Hydrochloric Acid SCHEMBL7278512 | 0.86 | PDE5A (0.69) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL7605721 | 0.80 | ALDH1A1 (0.50) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL7611350 | 0.79 | ALDH1A1 (0.49) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL7280806 | 0.79 | PDE5A (1.00) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL7606571 | 0.78 | ALDH1A1 (0.48) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| Hydrochloric Acid SCHEMBL7279655 | 0.78 | PDE5A (0.97) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL7607040 | 0.77 | ALDH1A1 (0.48) | PDE5ATBXAS1PTGS1PTGS2PDE3B | |
| SCHEMBL4859938 | 0.76 | RAD52 (0.69) | PDE5ATBXAS1PTGS1PTGS2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | claimed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | claimed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | claimed |
| US-20070197560-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2007-08-23 | — | — | US | disclosed |
| US-20040214831-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2004-10-28 | — | — | US | disclosed |
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | OSI PHARMACEUTICALS, INC. | 2002-02-28 | — | — | US | disclosed |
| US-20010055570-A1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives | NAEF RETO (CH) | 2001-12-27 | — | — | US | disclosed |
| EP-0579496-B1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-5439895-A | Cardiovascular disorders; inhibitor of thromboxane A2 synthetase and cyclic guanosine 3',5'-monophosphate | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| US-5436233-A | Nervous system disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0579496-A1 | 4-Aminoquinazoline derivatives, and their use as medicine | ONO PHARMACEUTICAL CO., LTD. (JP) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025968-A1 | Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives | VHL, MCL1, NFATC1 | PDE5A 3794/4885TBXAS1 977/4885PTGS1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.